

Press Release

Pure Protein L.L.C. To Supply Dynal Biotech Ltd. with HLA Proteins

Oklahoma City, OK and Austin, TX, October 15, 2002 – Emergent Technologies, Inc. (“ETI”) announced today that one of its biotech companies, Pure Protein, L.L.C., has been entered into a contract with UK-based Dynal Biotech Ltd. (www.tissue-typing.com) to supply HLA (Human Leukocyte Antigens) molecules covering a large number of specificities in milligram quantities. Dynal will use the molecules to produce test kits for matching organ transplant donors and recipients. The test kits will be introduced to the \$50 million dollar market in 2003. The initial term of the agreement is three years. Additional terms were not disclosed.

John Hoopingarner, Pure Protein COO, commented, “The uniqueness of the Pure Protein molecules allows Dynal to introduce a superior diagnostic test kit to the market which should improve the accuracy of the results with a very short turnaround period. We are delighted to be working with Dynal. The molecules will be supplied from Pure Protein’s lab in Oklahoma City.”

Dr. William Hildebrand, Pure Protein Chief Scientist, also noted, “This contract is very important to our gaining a foothold in the transplantation market. From this application we are confident of leveraging our HLA technology and immune system know-how to additional applications in vaccine discovery and validation, solving immunomodulation problems, and finding ways to train the immune system to better react to diseases such as cancer.” For more information, visit the Pure Protein website at www.pureproteinllc.com

Tommy Harlan founded Pure Protein L.L.C. in 1999 and together with Rick Hodgins also directs the activities of ETI and its other portfolio companies. ETI is a venture capital firm that specializes in forming, funding, commercializing, and managing biotech companies for the purpose of converting institutional and university-based technology into high return ventures. Its unique process matches breakthrough technology with commercialization partners who can validate the market potential and expeditiously bring the technology to market. Investors can have confidence that risks will be reduced and the time to liquidity accelerated because ETI’s process avoids unproven technologies, large front-end investments, and dependency on the IPO market. Visit its website at www.emergenttechnologies.com